Apeloa PharmaceuticalLtd's performance is commendable, especially its high rate of return and impressive earnings growth. The company's future earnings growth is expected to be similar to its current growth rate.

Apeloa Pharmaceutical's low P/E ratio is justified by expected slower growth. Shareholders accept this as they anticipate future earnings may not provide pleasant surprises, potentially limiting a strong share price rise.